D D Waters

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes
    David D Waters
    Division of Cardiology, San Francisco General Hospital and University of California at San Francisco, San Francisco, California 94114, USA
    J Am Coll Cardiol 61:148-52. 2013
  2. doi request reprint Utility of biomarkers and imaging in the development of drugs for the treatment of coronary atherosclerosis
    David D Waters
    Division of Cardiology, San Francisco General Hospital, and the Department of Medicine, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94965, USA
    Can J Cardiol 28:687-92. 2012
  3. ncbi request reprint Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
    David D Waters
    University of California, San Francisco School of Medicine, San Francisco, California 94110, USA
    Am J Cardiol 93:154-8. 2004
  4. ncbi request reprint Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection
    Priscilla Y Hsue
    Room 5G1, Division of Cardiology, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110
    Circulation 109:316-9. 2004
  5. ncbi request reprint Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study
    David D Waters
    University of California, San Francisco, California, USA
    J Am Coll Cardiol 48:1793-9. 2006
  6. doi request reprint Clinical insights from the Treating to New Targets trial
    David D Waters
    Division of Cardiology, San Francisco General Hospital, University of California, San Francisco, CA, USA
    Prog Cardiovasc Dis 51:487-502. 2009
  7. ncbi request reprint Safety of high-dose atorvastatin therapy
    David D Waters
    Division of Cardiology, San Francisco General Hospital and the School of Medicine, University of California, San Francisco, California 94110, USA
    Am J Cardiol 96:69F-75F. 2005
  8. ncbi request reprint What the statin trials have taught us
    David D Waters
    Division of Cardiology, San Francisco General Hospital, California, USA
    Am J Cardiol 98:129-34. 2006
  9. doi request reprint Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals
    David D Waters
    Division of Cardiology, San Francisco General Hospital and University of California, San Francisco, CA 94114, USA
    Circulation 120:28-34. 2009
  10. doi request reprint Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation
    David D Waters
    Division of Cardiology, San Francisco General Hospital, San Francisco, California 94114, USA
    J Am Coll Cardiol 54:1434-7. 2009

Detail Information

Publications56

  1. doi request reprint Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes
    David D Waters
    Division of Cardiology, San Francisco General Hospital and University of California at San Francisco, San Francisco, California 94114, USA
    J Am Coll Cardiol 61:148-52. 2013
    ..The purpose of this study was to compare the incidence of new-onset diabetes (NOD) with cardiovascular (CV) event reduction at different levels of NOD risk...
  2. doi request reprint Utility of biomarkers and imaging in the development of drugs for the treatment of coronary atherosclerosis
    David D Waters
    Division of Cardiology, San Francisco General Hospital, and the Department of Medicine, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94965, USA
    Can J Cardiol 28:687-92. 2012
    ..In summary, favourable effects on lipid biomarkers often do not translate into clinical benefit, and imaging trials, which focus on a narrow measurement of atherosclerosis, are also often not helpful...
  3. ncbi request reprint Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
    David D Waters
    University of California, San Francisco School of Medicine, San Francisco, California 94110, USA
    Am J Cardiol 93:154-8. 2004
    ..9 mmol/L) can provide additional clinical benefit...
  4. ncbi request reprint Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection
    Priscilla Y Hsue
    Room 5G1, Division of Cardiology, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110
    Circulation 109:316-9. 2004
    ..Patients with HIV infection exhibit increased rates of coronary events; however, the clinical features of acute coronary syndromes (ACS) in HIV-infected patients have not been well defined...
  5. ncbi request reprint Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study
    David D Waters
    University of California, San Francisco, California, USA
    J Am Coll Cardiol 48:1793-9. 2006
    ..We sought to assess the effects on cerebrovascular events of treating patients with stable coronary disease with low-density lipoprotein cholesterol (LDL-C) levels substantially below 100 mg/dl...
  6. doi request reprint Clinical insights from the Treating to New Targets trial
    David D Waters
    Division of Cardiology, San Francisco General Hospital, University of California, San Francisco, CA, USA
    Prog Cardiovasc Dis 51:487-502. 2009
    ..In summary, wider use of the 80-mg dose of atorvastatin in patients with stable coronary disease is safe, cost-effective, and provides an incremental reduction in coronary events...
  7. ncbi request reprint Safety of high-dose atorvastatin therapy
    David D Waters
    Division of Cardiology, San Francisco General Hospital and the School of Medicine, University of California, San Francisco, California 94110, USA
    Am J Cardiol 96:69F-75F. 2005
    ..The clinical benefits of preventing vascular events, myocardial infarction, stroke, and need for revascularization outweigh the low rates of adverse events associated with high-dose statin therapy in high- and intermediate-risk patients...
  8. ncbi request reprint What the statin trials have taught us
    David D Waters
    Division of Cardiology, San Francisco General Hospital, California, USA
    Am J Cardiol 98:129-34. 2006
    ..Translating this information into clinical practice presents a challenge: many patients who would benefit from statins remain untreated or undertreated or discontinue treatment soon after it is initiated...
  9. doi request reprint Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals
    David D Waters
    Division of Cardiology, San Francisco General Hospital and University of California, San Francisco, CA 94114, USA
    Circulation 120:28-34. 2009
    ..Information about physicians' adherence to cholesterol management guidelines remains scant. The present survey updates our knowledge of lipid management worldwide...
  10. doi request reprint Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation
    David D Waters
    Division of Cardiology, San Francisco General Hospital, San Francisco, California 94114, USA
    J Am Coll Cardiol 54:1434-7. 2009
    ..Guidelines prove their utility when their implementation improves outcomes across a broad population at risk, such as in this instance...
  11. doi request reprint Exploring new indications for statins beyond atherosclerosis: Successes and setbacks
    David D Waters
    Division of Cardiology, San Francisco General Hospital, and the Department of Medicine, University of California, San Francisco, CA, USA
    J Cardiol 55:155-62. 2010
    ..In conclusion, although statins are effective, established therapy for the prevention of vascular events in patients at risk, they have as yet not proven to be successful for these newer indications...
  12. doi request reprint Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials
    David D Waters
    Division of Cardiology, San Francisco General Hospital, and University of California at San Francisco, San Francisco, California 94114, USA
    J Am Coll Cardiol 57:1535-45. 2011
    ..We sought to examine the incidence and clinical predictors of new-onset type 2 diabetes mellitus (T2DM) within 3 large randomized trials with atorvastatin...
  13. ncbi request reprint Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial
    David D Waters
    Division of Cardiology, Room 5G1, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110, USA
    JAMA 288:2432-40. 2002
    ..Hormone replacement therapy (HRT) and antioxidant vitamins are widely used for secondary prevention in postmenopausal women with coronary disease, but no clinical trials have demonstrated benefit to support their use...
  14. ncbi request reprint Early pharmacologic intervention and plaque stability in acute coronary syndromes
    D D Waters
    Division of Cardiology, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    Am J Cardiol 88:30K-36K. 2001
    ..It is hoped that a growing awareness of the benefits of early statin therapy to stabilize culprit lesions in ACS will lead to an increase in the proportion of coronary patients who will receive this beneficial therapy...
  15. ncbi request reprint What do the statin trials tell us?
    D D Waters
    Division of Cardiology, San Francisco General Hospital, University of California at San Francisco, 94110, USA
    Clin Cardiol 24:III3-7. 2001
    ..The broad range of the therapeutic effects of statins yields safe, effective management of hypercholesterolemia in current practice while also providing a foundation for additional therapeutic refinements in the future...
  16. ncbi request reprint What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
    D D Waters
    Division of Cardiology, San Francisco General Hospital, San Francisco, California 94110, USA
    Am J Cardiol 88:7J-16J. 2001
    ..Furthermore, 3 nonrandomized, observational studies have recently reported an improved outcome in statin-treated compared with untreated patients after acute coronary syndromes...
  17. ncbi request reprint Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy
    David D Waters
    Division of Cardiology, San Francisco General Hospital, and the University of California, San Francisco School of Medicine, San Francisco, Calif 94110, USA
    Circulation 106:1690-5. 2002
    ..4% in the placebo group to 14.8% in the atorvastatin group over the 16 weeks of the trial (P=0.048)...
  18. ncbi request reprint Are we aggressive enough in lowering cholesterol?
    D D Waters
    Cardiology Division, Department of Medicine, San Francisco General Hospital, San Francisco, California 94110, USA
    Am J Cardiol 88:10F-5F. 2001
    ..Evidence now substantially supports the urgency of physicians to aggressively target the lowering of LDL-C levels for the primary and secondary prevention of coronary disease...
  19. ncbi request reprint Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial
    D D Waters
    San Francisco General Hospital, San Francisco, USA
    Can J Cardiol 16:11A-3A. 2000
    ..Treatment with atorvastatin significantly reduced low density lipoprotein cholesterol levels, and was associated with a 36% reduction in ischemic events and a significant delay in time to first ischemic event...
  20. ncbi request reprint Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection
    Priscilla Y Hsue
    Division of Cardiology, San Francisco General Hospital, and the Department of Medicine, University of California, San Francisco, CA 94110, USA
    Circulation 109:1603-8. 2004
    ..HIV-infected patients may be at increased risk for coronary events. The purpose of this study was to identify predictors of carotid intima-media thickness (IMT) in HIV patients at baseline and to measure IMT progression over 1 year...
  21. ncbi request reprint Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses
    Priscilla Y Hsue
    Divisions of Cardiology, San Francisco General Hospital, University of California, San Francisco, USA
    AIDS 20:2275-83. 2006
    ....
  22. ncbi request reprint Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
    Prakash Deedwania
    Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine, San Francisco, CA, USA
    Lancet 368:919-28. 2006
    ....
  23. doi request reprint Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery
    Sanjiv J Shah
    Division of Cardiology, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
    J Am Coll Cardiol 51:1938-43. 2008
    ....
  24. ncbi request reprint The effects of hydroxy-methyl-glutaryl co-enzyme A reductase inhibitors on platelet thrombus formation
    Paul D Thompson
    Section of Preventive Cardiology, Division of Cardiology, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA
    Atherosclerosis 161:301-6. 2002
    ....
  25. ncbi request reprint Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease
    Satyendra Giri
    Nuclear Cardiology Laboratory, Division of Cardiology, Hartford Hospital, and the Department of Medicine and Nuclear Medicine, University of Connecticut School of Medicine, Farmington, CT 06102 5037, USA
    Circulation 105:32-40. 2002
    ..Coronary artery disease can develop prematurely and is the leading cause of death among diabetics, making noninvasive risk stratification desirable...
  26. ncbi request reprint Racial differences of lipoprotein subclass distributions in postmenopausal women
    Amit N Vora
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ethn Dis 18:176-80. 2008
    ..We assessed racial differences in lipoprotein particle size, a marker of atherosclerosis risk, among women with coronary disease...
  27. doi request reprint Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study)
    Colleen Johnson
    University of California San Francisco, San Francisco, CA, USA
    Am J Cardiol 102:1312-7. 2008
    ..5 mg/dl (2.1 mmol/L) with atorvastatin 80 mg/day in patients with previous PCI reduces major cardiovascular events by 21% and repeat revascularizations by 27% compared with a less intensive lipid-lowering regimen...
  28. ncbi request reprint Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men
    S Giri
    Division of Cardiology, Hartford Hospital, CT 06102 5037, USA
    Atherosclerosis 137:359-66. 1998
    ..We conclude that oral estrogen in men reduces homocysteine, fibrinogen, and PAI-1 concentrations and favorably influences VLDL, LDL and HDL subclass levels without increasing markers of thrombotic risk...
  29. ncbi request reprint Lupus-related mitral valve disease: embolic coronary occlusion as a unique cause of myocardial infarction
    S Giri
    Division of Cardiology, Hartford Hospital, Connecticut 06102 5037, USA
    Can J Cardiol 13:859-63. 1997
    ..Mitral valve involvement in lupus is no longer limited to the small benign lesions described by Libman and Sacks...
  30. ncbi request reprint Implications of cigarette smoking for the management of patients with acute coronary syndromes
    Louise Metz
    Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco School of Medicine, San Francisco, CA 94110, USA
    Prog Cardiovasc Dis 46:1-9. 2003
    ..By 4 years the risk is only slightly higher than the risk of a subject who never smoked...
  31. ncbi request reprint Differences in medical care and disease outcomes among black and white women with heart disease
    Ashish K Jha
    Division of General Medicine, San Francisco VA Medical Center, San Francisco, USA
    Circulation 108:1089-94. 2003
    ..We sought to evaluate differences in medical care and clinical outcomes among black and white women with established coronary artery disease...
  32. ncbi request reprint Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study
    Kiran K Khush
    Division of Cardiology, University of California, San Francisco School of Medicine, San Francisco, Calif, USA
    Circulation 115:576-83. 2007
    ..Statins reduce the rate of major cardiovascular events in high-risk patients, but their potential benefit as treatment for heart failure (HF) is less clear...
  33. ncbi request reprint Role of thrombotic and fibrinolytic factors in acute coronary syndromes
    Masahiko Saigo
    Division of Cardiology, San Francisco General Hospital, and Department of Medicine, University of California, San Francisco, USA
    Prog Cardiovasc Dis 46:524-38. 2004
    ..The study of hemostatic factors in relation to these drugs has provided insights into understanding how these drugs produce beneficial effects...
  34. ncbi request reprint Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes
    R R Azar
    Division of Cardiology, Hartford Hospital and the University of Connecticut School of Medicine, USA
    J Am Coll Cardiol 32:1996-2002. 1998
    ..The purpose of this study was to compare the outcome of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (MI) when performed with or without the platelet glycoprotein IIb/IIIa antibody, abciximab...
  35. ncbi request reprint Acute aortic dissection related to crack cocaine
    Priscilla Y Hsue
    Division of Cardiology, San Francisco General Hospital, CA 94110, USA
    Circulation 105:1592-5. 2002
    ..Although single case reports have described acute aortic dissection in relation to cocaine use, this condition is not widely recognized, and the features of cocaine-related aortic dissection have not been defined...
  36. ncbi request reprint What a cardiologist needs to know about patients with human immunodeficiency virus infection
    Priscilla Y Hsue
    Division of Cardiology, San Francisco General Hospital, Department of Medicine, University of California, San Francisco, CA, USA
    Circulation 112:3947-57. 2005
    ..His total cholesterol was 331 mg/L, his HDL cholesterol was 27 mg/L, his triglycerides were 935 mg/L, and his LDL cholesterol could not be calculated. How should this patient be evaluated and managed?..
  37. doi request reprint Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (Data from the Treating to New Targets [TNT] trial)
    Jennifer E Ho
    Division of Cardiology, San Francisco General Hospital, and Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco, California, USA
    Am J Cardiol 105:905-11. 2010
    ..In particular, a HR at rest of > or =70 beats/min was associated with a 40% increased risk of all-cause mortality and more than doubled the risk of heart failure hospitalization, but not the risk of stroke or myocardial infarction...
  38. ncbi request reprint Effects of statin therapy on the development and progression of heart failure: mechanisms and clinical trials
    Kiran K Khush
    Division of Cardiology, University of California, San Francisco School of Medicine, San Francisco, California 94143, USA
    J Card Fail 12:664-74. 2006
    ..Statin therapy may therefore yield important clinical benefits in patients with heart failure-a physiologic state characterized by systemic inflammation and endothelial dysfunction...
  39. ncbi request reprint Cardiac arrest in patients who smoke crack cocaine
    Priscilla Y Hsue
    Division of Cardiology, San Francisco General Hospital, San Francisco, California, USA
    Am J Cardiol 99:822-4. 2007
    ..In patients with cardiac arrest, cocaine users are younger than nonusers and more likely to survive with neurologic recovery, even compared with age-matched controls with cardiac arrest...
  40. ncbi request reprint Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, proteins C and S, tissue factor, D-dimer, and prothrombin fragment 1 + 2 in men with acute myocardial infarction </=45 years of age
    Masahiko Saigo
    Division of Cardiology, San Francisco General Hospital, and the University of California, San Francisco, San Francisco, California, USA
    Am J Cardiol 94:1410-3. 2004
    ..Plasma levels of soluble fibrin and C-reactive protein were significantly higher in patients than in controls. On multivariate regression analysis, soluble fibrin was the strongest predictor of myocardial infarction at a young age...
  41. ncbi request reprint Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study
    Scott Kinlay
    Cardiovascular Division, Veterans Affairs Boston Healthcare System, West Roxbury, Mass, USA
    Arterioscler Thromb Vasc Biol 28:142-7. 2008
    ..We measured markers of inflammation in the MIRACL study, a randomized trial of atorvastatin versus placebo in acute coronary syndromes, to assess the relationship of inflammation to stroke...
  42. pmc Does prevalence of the metabolic syndrome in women with coronary artery disease differ by the ATP III and IDF criteria?
    Todd M Brown
    Health Services Research Training Program, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Womens Health (Larchmt) 17:841-7. 2008
    ..Whether the IDF definition identifies a greater prevalence of the metabolic syndrome than the ATP III definition in women with coronary artery disease (CAD) is unknown...
  43. doi request reprint The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics
    Roy W Jones
    RICE The Research Institute for the Care of Older People, Royal United Hospital, Bath, United Kingdom
    Alzheimers Dement 4:145-53. 2008
    ....
  44. ncbi request reprint Usefulness of serum endothelin levels in predicting death and myocardial infarction but not coronary progression in postmenopausal women with coronary disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study)
    Bernice Ruo
    Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Am J Cardiol 96:335-8. 2005
    ..8-fold increased risk of death or myocardial infarction. After adjustment for potential confounders, endothelin-1 remained a predictor of clinical events but was not correlated with angiographic progression...
  45. ncbi request reprint Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    John C LaRosa
    State University of New York Health Science Center, Brooklyn, NY 11203, USA
    N Engl J Med 352:1425-35. 2005
    ..We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD)...
  46. ncbi request reprint Effects of torcetrapib in patients at high risk for coronary events
    Philip J Barter
    Heart Research Institute, Camperdown, Sydney, NSW, Australia
    N Engl J Med 357:2109-22. 2007
    ..We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib...
  47. ncbi request reprint Statin therapy in acute coronary syndrome
    Vincent E Friedewald
    University of Texas Health Sciences Center at Houston, Houston, Texas, USA
    Am J Cardiol 99:213-21. 2007
  48. ncbi request reprint Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002 : Section 4: lessons from hormone replacement trials
    David D Waters
    Circulation 109:e53-5. 2004
  49. ncbi request reprint Effect of ACAT inhibition on the progression of coronary atherosclerosis
    Steven E Nissen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:1253-63. 2006
    ..The enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT) esterifies cholesterol in a variety of tissues. In some animal models, ACAT inhibitors have antiatherosclerotic effects...
  50. ncbi request reprint Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial
    Mark Kelemen
    University of Maryland Medical Center, 419 West Redwood Street, Suite 550, Baltimore, Maryland 21201, USA
    Atherosclerosis 179:193-200. 2005
    ....
  51. ncbi request reprint Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance
    Barbara V Howard
    MedStar Research Institute, 6495 New Hampshire Ave, Suite 201, Hyattsville, MD 20783, USA
    Circulation 110:201-6. 2004
    ..In this study, we hypothesized that PHT would have a worse effect on disease among women with AGT...
  52. ncbi request reprint Estrogen therapy for unstable angina: another bump for the bandwagon
    David D Waters
    J Am Coll Cardiol 39:238-40. 2002
  53. ncbi request reprint Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: executive summary
    Noel Bairey Merz
    Circulation 109:805-7. 2004
  54. doi request reprint Preventing and treating stroke and transient ischemic attack
    Doreen DeFaria Yeh
    Am J Cardiol 101:270-3. 2008
  55. ncbi request reprint Reassessment of National Cholesterol Education Program Adult Treatment Panel-III guidelines: one year later
    Benjamin J Ansell
    Am J Cardiol 90:524-5. 2002